Lee Cohen

Brittany Albright, MD, MPH, is a Harvard-trained, triple board-certified psychiatrist with expertise in interventional psychiatry, addiction psychiatry, and obesity medicine. She completed her adult psychiatry residency at Massachusetts General Hospital and McLean Hospital, followed by fellowship training in Addiction Psychiatry at the Medical University of South Carolina (MUSC). She currently serves as an Affiliate Assistant Professor of Psychiatry at MUSC.

Dr. Albright is the Founder and CEO of Sweetgrass Psychiatry, South Carolina’s largest physician-owned psychiatry practice, with three locations and a multidisciplinary team of 25+ clinicians. A leader in advancing access to innovative care, Sweetgrass Psychiatry was the first practice to launch esketamine in South Carolina in 2019 and has since developed a comprehensive interventional psychiatry program incorporating esketamine, ketamine, long acting injectables, and transcranial magnetic stimulation.

Her academic work includes numerous abstracts presented at national meetings and peer-reviewed publications spanning innovative psychiatric treatments and medical education. A nationally recognized speaker and consultant, Dr. Albright serves as President of the South Carolina Psychiatric Association and holds multiple leadership roles with Psych Congress, including Co-Chair of Psych Congress Elevate. She also created the Private Practice Summit, a national educational program focused on advancing independent psychiatric practice.

Her clinical approach integrates psychodynamic psychotherapy, mentalization-based therapy, and motivational interviewing with evidence-based pharmacologic and interventional treatments. She enjoys treating patients across the spectrum of psychiatric illness, with particular interests in complex mood and psychotic disorders and substance use disorders. She is trained and certified in transcranial magnetic stimulation and psychedelic-assisted psychotherapy.

Lee S. Cohen, MD, is an Associate Professor of Clinical Psychiatry at Columbia University Irving Medical Center, maintains a clinical practice focused on expert and complex diagnostics, and is considered an international expert in clinical psychopharmacology. He is also the director of the Clinical Neuroscience Center, LLP involved in innovative development and discovery of new compounds for neuropsychiatric conditions and directly consults with multiple pharmaceutical companies worldwide.

He is a senior reviewer for multiple journals, including the Journal of Child and Adolescent Psychopharmacology, the Journal of Developmental and Physical Disabilities, and the International Journal of Autism and Related Disabilities.
Dr Cohen teaches and presents research domestically and internationally at meetings such as the American Psychiatric Association and at Major Universities around the country. He is the recipient of the 2026 Weill Cornell Medicine/New York Presbyterian/Columbia New York-Presbyterian Child and Adolescent Psychiatry Residency Training Program-Outstanding Service Award.

Dr. Zinzuvadia is the founder and director of Park Avenue Wellness Center and is board certified in both Adult and Geriatric psychiatry. He directs the psychiatric services of several residential treatment facilities while also managing a comprehensive outpatient practice in Manhattan's Upper East Side.

He received his M.D. from SUNY Downstate College of Medicine and completed his residency training in psychiatry at New York Medical College in Valhalla, NY. He completed fellowship training in geriatric psychiatry at Weill Cornell Medical College.

He has implemented programs using long acting antipsychotic injections to decrease hospital readmission rates for treatment resistant schizophrenic patients across New York. He has an expertise in treating elderly patients both in the office setting and using in-home visits. He has been able to work with families to keep patients stable and at home instead of being placed into nursing facilities.

Dr. Zinzuvadia's research and clinical interests include the use of long acting antipsychotics in treatment resistant patients, cognitive dysfunction and treatment resistant depression in older adults, and the role of novel psychopharmacological agents including ketamine infusions in treatment resistant mood disorders. He is also helping to pioneer the use of technological interventions to increase access to quality psychiatric care. He directs a program for treatment resistant depression at the Park Avenue Wellness Center using a combination of comprehensive assessment and psychopharmacology, IV Ketamine infusions, and psychotherapy.